Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel.
作者： Oscar Arrieta , Pablo Anaya , Vicente Morales-Oyarvide , Laura Alejandra Ramírez-Tirado , Ana C. Polanco
DOI: 10.1007/S10198-015-0726-5
关键词:
摘要: Assess the cost-effectiveness of an EGFR-mutation testing strategy for advanced NSCLC in first-line therapy with either gefitinib or carboplatin–paclitaxel Mexican institutions. Cost-effectiveness analysis using a discrete event simulation (DES) model to simulate two therapeutic strategies patients NSCLC. Strategy one included tested and given accordingly. chemotherapy all without testing. All results are presented 2014 US dollars. The was made data from frequency EGFR-mutation. A univariate sensitivity conducted on EGFR prevalence. Progression-free survival (PFS) transition probabilities were estimated IPASS simulated Weibull distribution, run parallel trials calculate probabilistic analysis. PFS 6.76 months (95 % CI 6.10–7.44) vs 5.85 months 5.43–6.29) non-testing group. one-way showed that has direct relationship prevalence, while ICER cost have inverse iterations had incremental costs 1 comparison 2. There is between testing, prevalence When is >10 % remains constant. This study could impact Latin American health policies regarding mutation detection treatment
springer.com
sci-hub.se 参考文章(47)
Edward S Kim, Vera Hirsh, Tony Mok, Mark A Socinski, Radj Gervais, Yi-Long Wu, Long-Yun Li, Claire L Watkins, Mark V Sellers, Elizabeth S Lowe, Yan Sun, Mei-Lin Liao, Kell Østerlind, Martin Reck, Alison A Armour, Frances A Shepherd, Scott M Lippman, Jean-Yves Douillard, Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial The Lancet. ,vol. 372, pp. 1809- 1818 ,(2008) , 10.1016/S0140-6736(08)61758-4
Elizabeth A. Handorf, Sean McElligott, Anil Vachani, Corey J. Langer, Mirar Bristol Demeter, Katrina Armstrong, David A. Asch, Cost Effectiveness of Personalized Therapy for First-Line Treatment of Stage IV and Recurrent Incurable Adenocarcinoma of the Lung Journal of Oncology Practice. ,vol. 8, pp. 267- 274 ,(2012) , 10.1200/JOP.2011.000502
Stephen G Spiro, Gerard A Silvestri, The treatment of advanced non-small cell lung cancer. Current Opinion in Pulmonary Medicine. ,vol. 11, pp. 287- 291 ,(2005) , 10.1097/01.MCP.0000166590.03042.56
Marie Westwood, Manuela Joore, Penny Whiting, Thea van Asselt, Bram Ramaekers, Nigel Armstrong, Kate Misso, Johan Severens, Jos Kleijnen, Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis Health Technology Assessment. ,vol. 18, pp. 1- 166 ,(2014) , 10.3310/HTA18320
Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe, Shunichi Negoro, Isamu Okamoto, Junji Tsurutani, Takashi Seto, Miyako Satouchi, Hirohito Tada, Tomonori Hirashima, Kazuhiro Asami, Nobuyuki Katakami, Minoru Takada, Hiroshige Yoshioka, Kazuhiko Shibata, Shinzoh Kudoh, Eiji Shimizu, Hiroshi Saito, Shinichi Toyooka, Kazuhiko Nakagawa, Masahiro Fukuoka, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncology. ,vol. 11, pp. 121- 128 ,(2010) , 10.1016/S1470-2045(09)70364-X
Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi, Shunichi Sugawara, Satoshi Oizumi, Hiroshi Isobe, Akihiko Gemma, Masao Harada, Hirohisa Yoshizawa, Ichiro Kinoshita, Yuka Fujita, Shoji Okinaga, Haruto Hirano, Kozo Yoshimori, Toshiyuki Harada, Takashi Ogura, Masahiro Ando, Hitoshi Miyazawa, Tomoaki Tanaka, Yasuo Saijo, Koichi Hagiwara, Satoshi Morita, Toshihiro Nukiwa, Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR The New England Journal of Medicine. ,vol. 362, pp. 2380- 2388 ,(2010) , 10.1056/NEJMOA0909530
Donna M. Graham, Natasha B. Leighl, Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine. Frontiers in Oncology. ,vol. 4, pp. 258- 258 ,(2014) , 10.3389/FONC.2014.00258
Frances A. Shepherd, José Rodrigues Pereira, Tudor Ciuleanu, Eng Huat Tan, Vera Hirsh, Sumitra Thongprasert, Daniel Campos, Savitree Maoleekoonpiroj, Michael Smylie, Renato Martins, Maximiliano van Kooten, Mircea Dediu, Brian Findlay, Dongsheng Tu, Dianne Johnston, Andrea Bezjak, Gary Clark, Pedro Santabárbara, Lesley Seymour, Erlotinib in previously treated non-small-cell lung cancer. The New England Journal of Medicine. ,vol. 353, pp. 123- 132 ,(2005) , 10.1056/NEJMOA050753
Oscar Arrieta, Andrés Felipe Cardona, Luis Corrales, Alma Delia Campos-Parra, Roberto Sánchez-Reyes, Eduardo Amieva-Rivera, July Rodríguez, Carlos Vargas, Hernán Carranza, Jorge Otero, Nikki Karachaliou, Horacio Astudillo, Rafael Rosell, None, The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer Lung Cancer. ,vol. 87, pp. 169- 175 ,(2015) , 10.1016/J.LUNGCAN.2014.12.009
Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, Tomohide Tamura, Kazuhiko Nakagawa, Jean-Yves Douillard, Yutaka Nishiwaki, Johan Vansteenkiste, Shinzoh Kudoh, Danny Rischin, Richard Eek, Takeshi Horai, Kazumasa Noda, Ichiro Takata, Egbert Smit, Steven Averbuch, Angela Macleod, Andrea Feyereislova, Rui-Ping Dong, José Baselga, None, Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 21, pp. 2237- 2246 ,(2003) , 10.1200/JCO.2003.10.038